Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2972326rdf:typepubmed:Citationlld:pubmed
pubmed-article:2972326lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0019764lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C1332717lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C1706438lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0018951lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0376152lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0085358lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0108779lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C1413244lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C2698600lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:2972326lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:2972326pubmed:issue5lld:pubmed
pubmed-article:2972326pubmed:dateCreated1988-12-8lld:pubmed
pubmed-article:2972326pubmed:abstractTextWe previously demonstrated that after allogeneic bone marrow transplantation (BMT) a subset of CD8, HNK1, and DR-positive T lymphocytes are able to inhibit CFU-GM and BFU-E growth with an HLA-DR restriction. In this study we investigated whether these cells, present in normal marrow in low concentration (less than 1%), play the same role. HNK1-positive sorted marrow cells forming rosettes (E+C) were able to inhibit BFU-E and CFU-GM growth when added back to the marrow E-C at a ratio of 1:10 (HNK1+ E+C/E-C) in a range from 40% to 60%. This inhibitory effect was also detected for a cellular ratio of 1:100, which is the normal marrow value for this subset of T cell. HNK1+ DR+-sorted E+C after double-immunofluorescent labeling also showed the same inhibitory activity as the HNK1+ E+C, whereas the negative fraction including all the other E+C had no detectable inhibitory activity. CD3 and CD8 antigens were also present on the membrane of these cells, as demonstrated in two cases by double-immunofluorescent labeling performed with anti-CD3 or anti-CD8 monoclonal antibodies (MoAbs) and HNK1 MoAb, respectively, and subsequent cell sorting. Blocking experiments, performed by adding in culture anti-CD4 and anti-CD8 MoAbs to HNK1+ T cells showed that only the last MoAb was able to prevent inhibition of hematopoietic colony growth. These results confirmed that one subset of CD3+, CD8+, HNK1+, and DR+ T cells was responsible for in vitro inhibition of normal hematopoiesis. In addition, this inhibition was genetically restricted to HLA-class II antigens, since in three co-culture experiments with unrelated bone marrow cells inhibition occurred only when cells with one haplo-identical HLA-DR antigen was added back to the culture. Indeed, this effect was really HLA-DR restricted, since in blocking experiments with different anti-HLA class II MoAbs (anti-DR, anti-DP, and anti-DQ MoAbs) only an anti-HLA-DR MoAb was able to prevent the colony growth inhibition by CD3+ HNK1+, or CD8+ HNK1+ E+C. In conclusion, the CD3+, HNK1+, CD8+, DR+ cells may be the T-cell subset able to inhibit normal hematopoiesis with an HLA-DR restriction.lld:pubmed
pubmed-article:2972326pubmed:languageenglld:pubmed
pubmed-article:2972326pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2972326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2972326pubmed:statusMEDLINElld:pubmed
pubmed-article:2972326pubmed:monthNovlld:pubmed
pubmed-article:2972326pubmed:issn0006-4971lld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:KatzAAlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:NakazawaMMlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:Breton-Gorius...lld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:VainchenkerWWlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:RochantHHlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:VernantJ PJPlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:VinciGGlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:HenriAAlld:pubmed
pubmed-article:2972326pubmed:authorpubmed-author:ZohairMMlld:pubmed
pubmed-article:2972326pubmed:issnTypePrintlld:pubmed
pubmed-article:2972326pubmed:volume72lld:pubmed
pubmed-article:2972326pubmed:ownerNLMlld:pubmed
pubmed-article:2972326pubmed:authorsCompleteYlld:pubmed
pubmed-article:2972326pubmed:pagination1616-21lld:pubmed
pubmed-article:2972326pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:meshHeadingpubmed-meshheading:2972326-...lld:pubmed
pubmed-article:2972326pubmed:year1988lld:pubmed
pubmed-article:2972326pubmed:articleTitleIn vitro inhibition of normal human hematopoiesis by marrow CD3+, CD8+, HLA-DR+, HNK1+ lymphocytes.lld:pubmed
pubmed-article:2972326pubmed:affiliationINSERM U.91, Service d'Hématologie Hôpital Henri Mondor, Créteil, France.lld:pubmed
pubmed-article:2972326pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2972326pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2972326pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2972326lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2972326lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2972326lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2972326lld:pubmed